RYTM: financial statements from SEC — TradeAlmanac

RYTM

Rhythm Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	60m	51m	49m	33m	33m	29m
Cost of revenue	7m	5m	6m	4m	4m	3m
Research and development	42m	46m	42m	37m	38m	30m
Selling, general and administrative	64m	52m	46m	39m	35m	36m
Operating expenses	112m	104m	94m	80m	77m	70m
Operating income	−52m	−53m	−45m	−47m	−44m	−40m
Pre-tax income	−55m	−53m	−46m	−49m	−44m	−32m
Income tax	545,000	111,000	337,000	80,000	−344,000	479,000
Net income	−56m	−53m	−47m	−49m	−44m	−32m
Earnings per share	−0.83	−0.82	−0.75	−0.81	−0.73	−0.55
Earnings per share, diluted	−0.83	−0.82	−0.75	−0.81	−0.73	−0.55
Weighted average shares	68m	66m	64m	63m	61m	61m
Weighted average shares, diluted	68m	66m	64m	63m	61m	61m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	62m	54m	52m	136m	106m	89m	48m	162m
Short-term investments	278m	335m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−44m	−40m
Share-based compensation	23m	13m
Investing cash flow	57m	25m
Financing cash flow	−5m	32m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)